Abstract 309P
Background
Immunotherapy with lenvatinib plus pembrolizumab (LP) prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced endometrial cancer. However, the predictive biomarker for this therapy is still unclear. Some studies on breast and prostate cancer have suggested that expression of hormone receptors (HRs) has immune regulatory functions. Therefore, we explored whether the HRs expression could be a predictive biomarker of LP therapy.
Methods
We retrospectively reviewed clinicopathological information on patients with advanced mismatch repair proficient (pMMR) endometrial cancer who underwent LP therapy between January 2022 and March 2023 at the National Cancer Center Hospital. Expression of HRs was evaluated for estrogen receptor (ER) and progesterone receptor (PR) by immunohistochemistry. Cases were dichotomized, using 10% as a cut-off value. Expression of p53 and programmed cell death ligand-1 (PD-L1) were also confirmed. PFS and OS were compared according to the status of HRs, p53, and PD-L1 expressions by log-rank test. Multivariate analysis using Cox proportional hazard model was performed to confirm the prognosis factor.
Results
A total of 19 patients were reviewed, including four patients with carcinosarcoma. Twelve patients were ER-positive and 11 were PR-positive. Thirteen had an aberrant type of p53 expression and, 14 had PD-L1 positive (combined positive score ≥ 1). No association was found between prognosis and expression status of PR, p53, or PD-L1. However, patients with ER-positive had a significantly poorer PFS (4.3 vs. 10.0 months, hazard ratio [HR]: 3.28, p = 0.038) than those with ER-negative. Multivariate analysis confirmed that ER-positive is a statistically poor prognostic factor for PFS. Similarly, ER-positive patients tended to have a poorer OS (6.2 vs. 11.5 months, HR: 1.92, p = 0.375) than ER-negative patients. Overall response rate was 42% and 71% for ER-positive and negative patients, respectively.
Conclusions
ER expression was associated with shorter PFS of LP therapy. ER expression in tumors was a negative predictive biomarker in LP therapy for advanced endometrial cancer with pMMR.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
T. Nishikawa: Financial Interests, Personal, Invited Speaker: MSD, Eisai. All other authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract